By-health Co., Ltd.

By-health Co., Ltd. has recently adjusted its evaluation, reflecting improved valuation metrics in the Pharmaceuticals & Biotechnology sector. The company reported a net profit of CNY 401.27 million, an 89.31% increase, and reduced raw material costs by 4.8%, showcasing its financial stability and resilience despite long-term growth challenges.

By-health Co., Ltd. has recently experienced an evaluation adjustment, highlighting its strong financial performance, including a significant net profit increase and improved liquidity. The company has shown resilience despite a negative return over the past year, with a balanced valuation and an appealing dividend yield for potential investors.

By-health Co., Ltd. has recently experienced a valuation adjustment, reflecting an improved assessment of its financial metrics. Key indicators include a P/E ratio of 28 and a dividend yield of 3.11%. The company has shown strong financial performance, with a net profit of CNY 401.27 million and reduced raw material costs.

By-health Co., a key player in the Pharmaceuticals & Biotechnology sector, experienced notable stock activity on October 15, 2025. The company has shown a weekly increase but faces challenges with flat monthly performance and a decline over the past year. It maintains a market cap of CNY 13,185 million and a dividend yield of 4.64%.